INTRODUCTION {#s1}
============

Lung cancer is a major disease burden that accounts for 1.2 million deaths globally every year \[[@R1]\]. Although substantial effort has been invested in lung cancer research, therapeutic outcomes are poor. Recently, the role of vitamin D has been recognized in several tumors, including lung carcinoma.

The two main sources of vitamin D are endogenous synthesis in the skin regulated by sunlight exposure and dietary intake. Vitamin D is hydroxylated in the liver to 25-hydroxyvitamin D \[25(OH)D\], which is the major circulating form and determinant of vitamin D status \[[@R2]\]. The second hydroxylation reaction occurs in renal proximal tubules, where the primary active form of vitamin D, 1, 25-dihydroxyvitamin D \[1,25(OH)~2~D\] is formed \[[@R3], [@R4]\]. Compared to 1,25(OH)~2~ D, serum 25(OH)D is a better indicator of vitamin D status because of its longer half-life.

Vitamin D participates in critical cell functions such as cell proliferation, apoptosis, differentiation, metastasis, and angiogenesis \[[@R5]--[@R9]\]. Epidemiologic studies exploring the relationship between vitamin D and the incidence and prognosis of lung cancer patients have provided conflicting results \[[@R5], [@R10]--[@R13]\]. Zhang *et al*. \[[@R14]\] and Chen *et al*. \[[@R15]\] published two meta-analyses that demonstrated inverse association between blood vitamin D and lung cancer risk. However, the relationship between vitamin D (or calcium) intake and lung cancer is unclear. Recent studies have suggested that solar ultraviolet irradiation is protective against breast cancer, prostate cancer, non-Hodgkin lymphoma \[[@R16]--[@R19]\]. People living at various latitudes receive different doses of ultraviolet irradiation that regulates vitamin D synthesis and influences cancer risk and prognosis. Therefore, the aim of this systematic meta-analysis was to add the latest publications to understand the association between various factors regulating vitamin D levels and lung cancer risk and survival.

RESULTS {#s2}
=======

Study selection {#s2_1}
---------------

After initial screening of 2122 abstracts that were identified from online research databases, 33 were considered for inclusion. After carefully reading the full texts, three studies were excluded because they were related to total cancer incidence or mortality rate \[[@R20]--[@R22]\]. Three other articles were excluded because they focused only on vitamin D receptor or gene polymorphisms \[[@R23]--[@R25]\]. Four publications \[[@R26]--[@R29]\] were excluded because they were repetitive studies of three other publications \[[@R30]--[@R32]\]. Two studies didn\'t provide the exact OR \[[@R25], [@R33]\], and we obtained data from one of them from the authors \[[@R25]\]. Finally, 22 studies were selected for this meta-analysis. The flowchart of the study search and selection process is reported in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of study selection process](oncotarget-08-81040-g001){#F1}

Study characteristics {#s2_2}
---------------------

The main characteristics of the 22 included studies are listed in Table [1](#T1){ref-type="table"}. All eligible studies were published from 2005 to 2016 and included 813801 participants. Among the 22 studies, 8 were performed in Europe, 9 in North America, 4 in Asia and one in Oceania. Six of the 22 studies were case-control studies that included lung cancer patients of different stages and normal individuals undergoing routine physical examinations as controls. The remaining 16 studies were cohort studies that recruited general population during health check-ups. Fasting serum samples were collected at the time of recruitment. Patients were categorized into the following 4 categories based on serum 25(OH)D levels: (1) sufficient levels, ≥ 20 ng/ml(50 nmol/L); (2) insufficient levels, 10--19.9 ng/ml (25--49.9 nmol/L); (3) deficient levels, 5--9.9 ng/ml (12.5--24.9 nmol/L); (4) severe deficient levels, \< 5 ng/ml (12.5 nmol/L). The enrolled papers exhibited moderate to high quality.

###### Characteristics of the selected studies

                                                OR     95% CI   Country   Follow-up period   Age (years)   Sex     Smokers (%)   Partipants         Lung cancer cases   Measurement                     
  --------------------------------------------- ------ -------- --------- ------------------ ------------- ------- ------------- ------------------ ------------------- ------------- --------- ------- ----------
  **Serum vitamin D and risk**                                                                                                                                                                          
  Kilkkinen, A. 2008 \[[@R82]\]                 0.72   0.43     1.19      Finland            24 y          49.6    Both          NG                 C:29.6              NG            6,937     122     RIA
  Weinstein, S.J. 2011 \[[@R83]\]               0.91   0.48     1.72      Finland            20 y          59      Male          NG                 C:100               NG            29,133    500     CLIA
  Afzal, S. 2013 \[[@R74]\]                     0.57   0.43     0.75      Denmark            28 y          58      Both          Ever smoker: 3.3   9,791               507           CLIA              
  Skaaby, T. 2014 (Monica10) \[[@R34]\]                                                                    40-71   Both          F:27.4             C:45.2              O:0.9         2,649     84      CTIA
  Skaaby, T. 2014 (Inter99) \[[@R34]\]          0.91   0.51     1,62      Denmark            11.3 y        30-60   Both          F:25.5             C:35.2              O:3.5         6,146     36      HPLC
  Skaaby, T. 2014 (Health2006) \[[@R34]\]                                                                  18-69   Both          F:32.3             C:22.2              O:3.2         3,409     6       ECLIA
  Wong, Y.Y. 2014 \[[@R76]\]                    0.99   0.59     1,68      Australia          6.7 y         77.9    Male          F:61.4             C:5.04              NG            4,208     101     CLIA
  Wang, X. 2015 \[[@R75]\]                      0.41   0.19     0.91      China              NG            57.1    Both          F:20               C:48                NG            200       100     LC/MS/MS
  Ordonez-Mena, J.M. 2016 (ESTHER) \[[@R31]\]   1.07   0.64     1.78      Germany            10 y          63      Both          F:31.6             C:16.5              NG            8,928     134     CLIA
  Ordonez-Mena, J.M. 2016 (TROMSØ) \[[@R31]\]   1.07   0.64     1.78      Germany            10 y          63      Both          F:31.6             C:16.5              NG            8,928     134     CLIA
  Wu, X. 2016 \[[@R25]\]                        0.74   0.51     1.19      China              NG            57.4    Both          NG                 C:59.1              NG            871       426     RIA
  **Vitamin D intake and risk**                                                                                                                                                                         
  Yumie Takata 2012 \[[@R30]\]                  0.66   0.48     0.91      China              11.2 y        59.1    Female        NG                 NG                  NG            71,267    428     NG
  Cheng, T. Y. 2013 \[[@R84]\]                  0.92   0.69     1.21      USA                7 y           63      Female        F:40.3             C:7.3               NG            128,779   1,771   NG
  **Vitamin D intake and risk**                                                                                                                                                                         
  Cheng, T. Y. 2014 \[[@R85]\]                  0.67   0.32     1.39      USA                4 y           60.8    Both          F:70.4             C29.6               NG            1,428     749     NG
  Redaniel, M. T. 2014 \[[@R86]\]               0.89   0.7      1.13      UK                 5 y           \> 55   Female        F:23.3             C:58.1              NG            6,750     484     NG
  Mahabir, S. 2010 \[[@R87]\]                   0.92   0.84     1.01      USA                7 y           50-71   Both          F:49.0             C:12                NG            482,875   7,052   NG
  Li, K. 2011 \[[@R88]\]                        0.71   0.14     1.21      German             11 y          35-64   Both          NG                 NG                  NG            24,323    147     NG
  Zhou, Wei 2005 \[[@R35]\]                     1.64   1.17     2.29      USA                NG            66      NG            F:5.7              C:4.4               NG            2,048     923     NG
  **Serum vitamin D and survival**                                                                                                                                                                      
  Zhou, W. 2007 \[[@R61]\]                      0.74   0.5      1.1       USA                72 m          68.6    Both          F:48.8             C:33.8              NG            NG        447     RIA
  Heist, R. S. 2008 \[[@R24]\]                  1.08   0.75     1.57      USA                42 m          62      Both          F:45               C:47                NG            NG        294     RIA
  Anic, G. M. 2014 \[[@R23]\]                   1.18   0.89     1.56      Finland            NG            58.6    Male          NG                 C:100               NG            NG        500     CLIA
  Vashi, P. G. 2015 \[[@R77]\]                  0.99   0.78     1.26      USA                10.8 m        57.4    Both          F:39.8             C:39.8              NG            NG        359     CLIA
  **Serum vitamin D and mortality**                                                                                                                                                                     
  Liu, Y. 2011 \[[@R89]\]                       2.54   1.01     6.41      China              72 m          NG      Both          NG                 NG                  NG            NG        568     ELISA
  Cheng, T. Y. 2012 \[[@R32]\]                  0.53   0.31     0.92      USA                12 y          43.7    Both          F:23.7             C:25.0              NG            16,693    258     RIA
  Tretli, S. 2012 \[[@R90]\]                    0.18   0.11     0.29      Norwegian          NG            56.5    Both          NG                 NG                  NG            658       210     RIA

NG: not given; RIA: radio-immunoassay; CLIA: chemiluminescent immunoassay; HPLC: high-performance liquid chromatography; ECLIA: electroluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; LCMS/MS: liquid chromatography tandem mass spectrometry; USA: United States; UK: United Kingdom; C: Current smoker; F: Former smoker; O: Occasional smoker; y: year; m: month.

Serum 25(OH)D levels and lung cancer risk {#s2_3}
-----------------------------------------

There was a decreased lung cancer risk in patients when comparing the highest vs. lowest levels of circulating 25(OH) D (OR = 0.93, 95% CI: 0.87--1.00, *p \<* 0.05) and heterogeneity I^2^ = 61.3%, *p* = 0.008 ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}). For the sensitivity analysis removal of the study by Skaaby *et al*. \[[@R34]\] reduced heterogeneity without significantly affecting OR (OR = 0.72, 95% CI: 0.61--0.85, *p \<* 0.001; I^2^ = 25.5%, *p* = 0.2255; Figure [2A](#F2){ref-type="fig"}).

![Forest plots analyzing (**A**) serum vitamin D levels and lung cancer risk; and (**B**) vitamin D dietary intake and lung cancer risk.](oncotarget-08-81040-g002){#F2}

Vitamin D intake and lung cancer risk {#s2_4}
-------------------------------------

Analysis of the 7 studies that evaluated the correlation between vitamin D (or calcium) intake and lung cancer risk showed pooled OR of 0.92 (95% CI: 0.85--1.00, *p \<* 0.05) and heterogeneity I^2^ = 64%, *p* = 0.01 (Figure [1B](#F1){ref-type="fig"}). The study by Zhou *et al*. \[[@R35]\] was eliminated by the sensitivity analysis and resulted in a pooled OR of 0.89, 95% CI: 0.83--0.97, *p \<* 0.01; I^2^ = 0%, *p* = 0.46 (Figure [2B](#F2){ref-type="fig"}).

Subgroup analysis based on smoking status demonstrated a negative association of lung cancer risk with nonsmokers (OR = 0.76, 95% CI: 0.65--0.88, *p \<* 0.01; I^2^ = 62.1%, *p* = 0.07; Figure [3A](#F3){ref-type="fig"}). However, there was no association with former smokers (OR = 0.98, 95% CI: 0.69--1.4, *p* = 0.92; I^2^ = 70.9%, *p* = 0.06) or current smokers (OR = 1, 95% CI: 0.63--1.60, *p* = 0.99; I^2^ = 0%, *p* = 0.85; Figure [3B--3C](#F3){ref-type="fig"}).

![Forest plots of subgroup analysis of vitamin D intake and lung cancer risk in (**A**) nonsmokers; (**B**) former smokers and (**C**) current smokers.](oncotarget-08-81040-g003){#F3}

Serum 25(OH)D levels and lung cancer survival {#s2_5}
---------------------------------------------

The multivariable-adjusted ORs (highest vs. lowest categories of 25(OH)D) of lung cancer survival and mortality with serum 25(OH)D are shown in Figure [4A](#F4){ref-type="fig"} and Figure [4B](#F4){ref-type="fig"}. The pooled OR = 1.01, 95% CI: 0.87--1.18, *p* = 0.87; I^2^ = 19.4%, *p* = 0.29 for survival and OR = 0.39, 95% CI: 0.28--0.54, *p \<* 0.01; I^2^ = 92.5%, *p \<* 0.01 for mortality. Patients with high 25(OH)D levels tend to have a better prognosis.

![Forest plots analyzing (**A**) serum vitamin D values and lung cancer survival; and (**B**) serum vitamin D values and lung cancer mortality.](oncotarget-08-81040-g004){#F4}

Publication bias and sensitivity analysis {#s2_6}
-----------------------------------------

Symmetrical funnel plots demonstrated that there was no publication bias in this meta-analysis ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Further, sensitivity analysis by removing single study in turns exhibited no disproportionate impact on the pooled estimates, which indicated the robustness of our research.

Latitude, annual sunshine exposure, vitamin D and lung cancer {#s2_7}
-------------------------------------------------------------

Some studies showed a positive correlation between the incidence of lung cancer and latitude \[[@R36], [@R37]\]. Lin *et al.* found that UVR exposure was associated with decreased risk of lung cancer \[H*R* = 0.86 (0.75, 0.98), *p \<* 0.5\] \[[@R38]\]. A Chinese study exhibited a 12% decrease in lung cancer mortality for every 10 mW/ (nm/m^2^) increase in UVB irradiance \[[@R39]\]. Due to insufficient data sources and high heterogeneity in available data, we failed to statistically prove that higher latitude and lower sun exposure resulted in higher incidence and mortality of lung cancer. Vitamin D synthesis partly relies on exposure to solar ultraviolet radiation, which is affected by duration of daily sunshine, latitude and season \[[@R40]\]. We compared vitamin D levels with annual sunshine exposure and latitude of the cities where the included researches were conducted. As expected, we discovered a positive relationship between vitamin D concentrations and annual sun exposure (*r* = 0.807, *p \<* 0.001) and a negative correlation between vitamin D levels and latitude (*r* = −0.62, *p \<* 0.01). This outcome indirectly verified our hypothesis.

DISCUSSION {#s3}
==========

In this meta-analysis, we comprehensively analyzed the relationship between vitamin D levels and lung cancer. Our results demonstrated an inverse association between serum 25(OH)D levels and lung cancer risk, which was consistent with findings by previous two meta-analyses \[[@R14]\]. Vitamin D (or calcium) intake was also negatively related to lung cancer risk. Subgroup analysis showed that vitamin D intake reduced lung cancer risk, especially in nonsmokers. Besides, a trend presented that high serum vitamin D levels reduced lung cancer mortality and improved survival. In relation to annual sun exposure and latitude, vitamin D levels positively correlated with extent of sun exposure, but negatively correlated with latitude.

Several possible mechanisms can explain the protective effects of vitamin D against lung cancer. Some studies have demonstrated that vitamin D regulates immunological function of lung epithelial cells and inhibits cellular proliferation and angiogenesis while promoting cellular differentiation and apoptosis \[[@R41]--[@R44]\]. It can enhance host defense by facilitating transcription of cathelicidin antimicrobial peptide genes and translation of CD14, a co-receptor for detecting bacterial lipopolysaccharide, both of which are vital for innate immunity in the lung \[[@R41]\]. In human lung tumor cell lines and mouse models, 1,25(OH)~2~D inhibits the angiogenesis and growth of cancer cells by suppressing the response to vascular endothelial growth factor (VEGF) \[[@R43]\]. Also, 1,25(OH)~2~D inhibits signaling pathways that promote lung cancer including mutations in K-Ras and epidermal growth factor receptor (EGFR), dysregulation of Wnt/β-catenin, which determines metastasis and proliferation \[[@R5], [@R45], [@R46]\]. In addition, 1,25(OH)~2~D upregulates secretion of E-cadherin and catenin, a glycoprotein that helps cell-cell adherence, thereby preventing metastases \[[@R47]\]. Moreover, 1,25(OH)~2~D represses the expression of cyclooxygenase-2 and inhibits prostaglandin synthesis, which can stimulate tumor cell proliferation and angiogenesis \[[@R48]\]. Finally, both lung cancer and chronic obstructive pulmonary disease (COPD) involve DNA damage, epithelial-to-mesenchymal transition (EMT) and airway inflammatory mechanisms \[[@R49], [@R50]\]. Skaaby *et al.* found inverse relationship between vitamin D status and COPD, thereby suggesting its association with lung cancer \[[@R51]\].

Subgroup analyses showed that vitamin D reduced lung cancer risk in non-smokers but not former or current smokers. Smokers had lower vitamin D intake \[[@R52], [@R53]\] and serum 25(OH)D levels \[[@R54]--[@R56]\]. Besides, 1,25(OH)~2~D is degraded by CYP24A1, a chemical substance that is activated by smoke-related carcinogen benzo\[a\]pyrene \[[@R57]\]. Therefore, higher serum vitamin D concentration or vitamin D intake may not have a positive biological effect among current smokers. We found a beneficial trend for higher vitamin D levels in former smokers than current smokers. This supports previous findings that quitting smoking increases both vitamin D intake and serum vitamin D status closer to levels of never smokers \[[@R58], [@R59]\]. It is plausible that smoking cessation restores metabolic functions of vitamin D.

Interestingly, there was no association between blood vitamin D levels with lung cancer survival in our analysis. There are several possible reasons to explain this finding. First, the vitamin D concentrations in our study were too low (average value = 17.7 ng/ml) to observe any significant impact on the prognosis. Clinically, vitamin D levels below 20 ng/ml are considered deficient \[[@R60]\]. Less physical activity, insufficient sunlight exposure and high latitude related to these chosen studies may account for low vitamin D levels. There is probably a threshold effect for serum vitamin D or differential effects for vitamin D from foods and supplements in regard to lung cancer prognosis. Second, the disease stage was far too advanced in the selected patients for vitamin D levels to influence prognosis. A US study collected serum samples from 447 early stage non-small cell lung cancer patients shortly after diagnosis and found higher circulating 25(OH)D correlated with longer survival, especially among early stage IB-IIB patients (AHR, 0.45; 95% CI, 0.24--0.82; *p* = 0.002) \[[@R61]\]. We can assume that malignant cells decreased the expression of vitamin D receptor or conversion of 25(OH)D to 1,25(OH)~2~D to escape the antiproliferative actions of vitamin D, and this may be more prevalent in advanced-stage cancers than earlier stages \[[@R62]\]. Thirdly, the various histological types of lung cancer in the selected studies may respond differently to vitamin D. Vitamin D suppressed growth of a lung squamous cell carcinoma (SCC) cell line, but not an adenocarcinoma cell line with higher vitamin D receptor mRNA levels in the SCC cell line compared to the adenocarcinoma cell line \[[@R63]\]. Lastly, vitamin D may not influence prognosis in advanced lung cancer patients.

Consistent with previous findings \[[@R64]--[@R66]\], we observed that poor sun exposure or high latitude resulted in reduced serum vitamin D levels. Latitude-dependent variability in the solar zenith angle and higher ozone columns far from the equator may contribute to this variation in UVB irradiation, thereby influencing variation in vitamin D production \[[@R66]\]. We further postulate that latitude, sun radiation and lung cancer may be linked through of the metabolic role of vitamin D or other unknown mechanisms. More studies are necessary to confirm these aspects conclusively.

Our study has few inherent potential limitations that should be considered. First, the selected studies evaluated circulating 25(OH)D levels with different measurements, and the time (time quantum, season) of collecting blood sample was not always consistent. Second, a meta-analysis of observational studies cannot fully explain the causative relation between vitamin D and lung cancer. As most of the included articles were prospective cohort studies and serum samples were collected at the time of initial recruitment, from a point we can assure it is low vitamin D leads to lung cancer, not the reverse causation. Third, Skaaby *et al.* reported that high physical activity, lower BMI, non-smoking, a healthier diet and higher alcohol intake were associated with higher 25(OH)D levels \[[@R56]\]. The original studies had already adjusted for such covariates and bias introduced by these potential confounding factors was probably minimized. Fourth, the quartiles for highest vs. lowest vitamin D categories varied among the different studies, which was an inherent bias in the quantitative assessment. Fifth, even though we attempted to perform our literature search as completely as possible, we were unable to obtain unpublished papers and our search language was restricted to English only. Despite these limitations, no significant heterogeneity was found, thereby indicating robustness of our meta-analysis. Also, funnel plot analysis didn\'t discover any publication bias, suggesting that the studies used for this analysis were representative of clinical circumstances.

In conclusion, our meta-analysis suggests that higher serum 25(OH) D and vitamin D intake is negatively linked with lung cancer incidence. Since sun exposure and latitudes affect vitamin D levels, our meta-analysis hints at their relationship with lung cancer, although more investigations are needed regarding this aspect. Also, well-designed randomized controlled trials are needed to explore the specific mechanistic relationship between vitamin D and lung cancer prognosis.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched relevant studies in computerized bibliographic databases, namely, Pubmed, Web of Science, EBSCO and Ovid MEDLINE. The language parameter for study search was set to English. The search terms were vitamin D, 25(OH)D, 1,25(OH)~2~D, lung cancer, solar and latitude. The last comprehensive search was performed on March 13, 2017. All cited references were also manually crosschecked for additional reports.

Study inclusion criteria and exclusion criteria {#s4_2}
-----------------------------------------------

The inclusion criteria for the studies were: (1) studies conducted on human populations and published in a peer-reviewed journal; (2) studies included case-control, cross-sectional, retrospective and prospective cohorts and assessed association between solar radiation, latitude, vitamin D \[vitamin D (or calcium) intake or serum 25(OH)D\] and lung cancer risk, survival and mortality; (3) studies reported OR, hazard ratio (HR) or relative risk (RR) with 95% CI; (4) univariate or multivariate analyses was performed to analyze potential confounders including age, living circumstance, body mass index, smoking status, years and pack years of smoking, education, physical activity, family history of lung cancer and alcohol consumption; (5) only the most comprehensive study was retrieved for overlapping publications.

The major exclusion criteria were as follows: (1) articles did not satisfy the above-mentioned inclusion criteria; (2) articles were case reports, letters, proceedings, abstracts, editorials or reviews; (3) unpublished sources of data.

Data extraction and quality assessment {#s4_3}
--------------------------------------

The following information was collected from each study: year of publication, first author, country, age, sex, number of participants, number of lung cancer cases and smokers, vitamin D levels, years of follow-up, OR (or RR, HR) and its 95% CI.

The quality of the selected studies was analyzed using the Newcastle-Ottawa Scale \[[@R67]\]. The literature selection, methodological quality assessment and data extraction process was conducted separately by two experienced reviewers and any disagreement was resolved by a third reviewer. This meta-analysis was performed in compliance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines \[[@R68]\] ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

Statistical analysis {#s4_4}
--------------------

Since the absolute lung cancer risk is relatively low, the RR and HR were mathematically equal to OR \[[@R69], [@R70]\] and therefore, we treated all results as OR \[[@R71]\]. The reported OR with their corresponding 95% CIs comparing highest and lowest levels of vitamin D were used to calculate pooled estimates for the meta-analysis (the lowest level category was the reference). If the original paper didn\'t use the lowest exposure level as the reference, the OR were recalculated with the method according to Greenland *et al.* \[[@R72]\] and Orsini *et al.* \[[@R73]\]. Therefore, raw data from 5 reports were recounted \[[@R31], [@R74]--[@R77]\].

The pooled OR and 95% CI were calculated by using fixed effects model according to generic inverse variance or random effects model using the DerSimonian-Laird method based on heterogeneity \[[@R78]\]. Heterogeneity was evaluated by employing the Cochran Q test with a *P* value greater than 0.05 suggesting no obvious heterogeneity \[[@R79]\]. The I^2^ test was also used to assess the heterogeneity between studies. I^2^ values of 25, 50, and 75% indicated low, moderate, and high heterogeneity, respectively \[[@R80]\]. When I^2^ was under 50%, studies with a relatively acceptable heterogeneity were considered, and the fixed-effects model was adopted; otherwise, a random effect model was employed. We also performed sensitivity analysis to explore the stability condition of pooled estimates by omitting single study at a time. Further, visual inspection of the funnel plot was used to detect the possible risk of publication bias \[[@R81]\]. The Spearman linear correlation analysis was used to analyze the relations between annual sunshine exposure, latitude and vitamin D. All meta- analyses were conducted with the STATA 12.0 (Stata Corporation, College Station, TX, USA) and RevMan 5.3 software (Cochrane Library, Oxford, UK). Spearman linear correlation analysis was operated with SPSS 17.0 (IBM, Chicago, IL, USA).
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=========================================
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